Lifeline Scientific Further Results from Machine Preservation Trial

Published: Aug 20, 2008

Lifeline Scientific, the medical technology company, announces further data from the Machine Preservation Trial comparing the LifePort® Kidney Transporter (“LifePort”) with the standard practice of static storage using ice in a cool box. These data were presented last week at the XXII International Congress of the Transplantation Society in Sydney, Australia.

The results demonstrate for the first time that kidneys from non-heart beating donors and from older donors are more likely to function immediately post transplantation when preserved with the LifePort Kidney Transporter than kidneys stored in the standard way. Non heart beating and older donors represent a significant potential new resource to help solve the global shortage of donor organs for transplant. A transplant patient who receives a kidney that does not work immediately will need to receive post–transplant dialysis treatment. Kidneys with delayed graft function (DGF) are also associated with an increased risk of organ rejection and greater costs to the healthcare system.

Highlights of the Results

· Statistically significant results showed that DGF was strongly reduced in transplanted kidneys from non-heart beating donors by using LifePort

· Primary non-function (complete failure immediately post transplant) of transplanted kidneys from older donors was significantly reduced when those kidneys were preserved using LifePort

· When DGF did occur after transplantation of kidneys from older deceased donors, six month graft survival was significantly better in kidneys preserved with LifePort

The trial was conducted in conjunction with Eurotransplant and Deutsche Stiftung Organ transplantation. David Kravitz, Chief Executive of Lifeline Scientific, said: “These results further demonstrate the advantages of LifePort over the traditional static ice box storage. LifePort has the potential to not only help improve the quality and number of kidneys available for transplantation but also improve outcomes for kidney transplant recipients and reduce the overall costs of kidney transplants.”

Lifeline Scientific, Inc. David Kravitz, CEO Seymour Pierce (Nomad) +44 (0)20 7107 8000 Mark Percy / Huaizheng Peng / Sarah Jacobs

Financial Dynamics +44 (0)20 7831 3113 Ben Brewerton / John Dineen

Back to news